Prudential Financial’s Cidara Therapeutics CDTX Stock Holding History

Prudential Financial’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,199	Closed	-$265K	–	2422
2025 Q4	$265K	Buy	+1,199	New	+$194K	﹤0.01%	2010
2024 Q2	–	Sell	-600	Closed	-$11K	–	2711
2024 Q1	$11K	Hold	600	–	–	﹤0.01%	2660
2023 Q4	$9.53K	Hold	600	–	–	﹤0.01%	2634
2023 Q3	$11.3K	Sell	600 -1,330	-69%	-$26.1K	﹤0.01%	2584
2023 Q2	$43.6K	Hold	1,930	–	–	﹤0.01%	2545
2023 Q1	$49K	Sell	1,930 -1,130	-37%	-$32.1K	﹤0.01%	2499
2022 Q4	$46.3K	Buy	3,060 +360	+13%	+$4.29K	﹤0.01%	2498
2022 Q3	$34K	Buy	+2,700	New	+$37.3K	﹤0.01%	2590

Prudential Financial's CDTX Position: Q1 2026 in Review

Prudential Financial sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 1,199 shares — an estimated $265K sold.

Prudential Financial first reported a position in CDTX in Q3 2022 and held it in 8 quarters. The position peaked at $265K in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Prudential Financial reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Prudential Financial sold 1,199 Cidara Therapeutics shares in Q1 2026, an estimated $265K.
Prudential Financial first reported a position in Cidara Therapeutics in Q3 2022 and held it in 8 quarters.
Prudential Financial's Cidara Therapeutics position peaked at $265K in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.